<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03968679</url>
  </required_header>
  <id_info>
    <org_study_id>M19SUS</org_study_id>
    <nct_id>NCT03968679</nct_id>
  </id_info>
  <brief_title>Lymph Drainage Mapping for Tailoring Elective Nodal Irradiation in Head and Neck Cancer</brief_title>
  <acronym>SUSPECT-2</acronym>
  <official_title>Mapping of Sentinel Lymph Node Drainage Using SPECT/CT to Tailor Highly Selective Elective Nodal Irradiation in Node-negative Neck of Patients With Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to explore the safety and outcome of lymph drainage mapping(LDM) to&#xD;
      individually tailor the elective nodal irradiation (ENI) to the ipsilateral neck only. The&#xD;
      goal is to exclude the contralateral negative neck from the irradiation fields when there is&#xD;
      no contralateral draining sentinel node. In case contralateral lymph drainage is found on&#xD;
      SPECT/CT, a contralateral sentinel node procedure (SNP) is performed to remove the draining&#xD;
      node. The patient will only receive contralateral ENI if (micro/macro)metastasis are found in&#xD;
      this contralateral sentinel node.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SUSPECT2 study is a modified concept from the first SUSPECT study (N14SUS). The first&#xD;
      study investigated whether lymph drainage mapping (LDM) using SPECT/CT was a safe and&#xD;
      feasible method to exclude the contralateral neck from irradiation, or, in case of&#xD;
      contralateral lymph drainage, to tailor the contralateral ENI field to the level containing&#xD;
      the tracer accumulation. In this study, large dose reductions to most organs at risk were&#xD;
      realized, as well as significant reductions of both short term (mucositis, dysphagia) and&#xD;
      long term (xerostomia, dysphagia) toxicities.&#xD;
&#xD;
      Firstly, the SUSPECT2 study aims to expand the inclusion criteria of the original SUSPECT&#xD;
      study. Secondly, it aims to further reduce the proportion of patients that undergoes&#xD;
      bilateral ENI, by performing a contralateral sentinel node procedure (SNP) in case of&#xD;
      contralateral lymph drainage. The patient will only receive contralateral ENI if&#xD;
      (micro/macro)metastasis are found in this contralateral sentinel node.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contralateral regional failure</measure>
    <time_frame>1 year</time_frame>
    <description>Cumulative incidence of contralateral regional metastasis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment toxicity</measure>
    <time_frame>Until 2 years after end of radiotherapy</time_frame>
    <description>Physician-rated early and late treatment toxicity (CTCAE v5.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>Until 18 months after end of radiotherapy</time_frame>
    <description>Health-related quality of life after treatment (EORTC QLQ-C30/HN35)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Unilateral elective nodal irradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exclusion of contralateral neck from elective nodal irradiation, based on results of SPECT/CT and (in case of contralateral drainage) contralateral sentinel node procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Unilateral elective nodal irradiation</intervention_name>
    <description>After injection of nanocolloid tracer submucosally around the tumor, patients undergo lymph drainage mapping (LDM) using SPECT/CT. If no contralateral drainage is visualized, the patient receives unilateral elective nodal irradiation (ENI). In case of contralateral lymph drainage, a contralateral sentinel node procedure is performed. If pathologic evaluation finds no metastasis, the patient receives unilateral ENI. If (micro/macro) metastasis are found, the patient will receive bilateral ENI.</description>
    <arm_group_label>Unilateral elective nodal irradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed and histopathologically proven primary HNSCC&#xD;
&#xD;
          -  T1-4N0-2b&#xD;
&#xD;
          -  Tumor does not cross midline&#xD;
&#xD;
          -  WHO performance status 0 or 1&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Distant metastatic spread at the time of inclusion&#xD;
&#xD;
          -  Chemotherapy or surgery (for the present tumor), prior to inclusion&#xD;
&#xD;
          -  Previous radiation treatment in the head and neck region, for any reason&#xD;
&#xD;
          -  Previous neck dissection&#xD;
&#xD;
          -  Recurrent or second primary tumor in the head and neck region&#xD;
&#xD;
          -  Head and neck malignancies arising from skin, lip, nose, sinuses, nasopharynx,&#xD;
             salivary glands, thyroid gland or esophagus&#xD;
&#xD;
          -  Pregnancy or no active contraception for pre-menopausal women&#xD;
&#xD;
          -  Known hypersensitivity to iodine or nanocolloid injection&#xD;
&#xD;
          -  Having any condition (physical, mental, sociological) that interferes with the&#xD;
             informed consent procedure and follow-up schedules&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abrahim Al-Mamgani, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abrahim Al-Mamgani, MD, PhD</last_name>
    <phone>+31205129111</phone>
    <email>a.almamgani@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pieter D de Veij Mestdagh, MD</last_name>
    <phone>+31205129111</phone>
    <email>p.d.veij@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abrahim Al-Mamgani, MD, PhD</last_name>
      <phone>+31 20 512 9111</phone>
      <email>a.almamgani@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>Pieter de Veij Mestdagh, MD</last_name>
      <phone>+31 20 512 9111</phone>
      <email>p.d.veij@nki.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 27, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>head and neck cancer</keyword>
  <keyword>lymph drainage mapping</keyword>
  <keyword>sentinel node procedure</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>unilateral elective neck irradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

